



MURAB is a research project funded by the European Union.

The Project involves a **consortium of 7 European partners**: Universities, Technical Research Institutes and Industrial partners in what we named a **clinical innovation triangle**. The project started in January 2016 and lasts for 4 years.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 688188.

PARTNERS

UNIVERSITIES

UNIVERSITY OF TWENTE.



UNIVERSITÀ di VERONA

TECHNICAL RESEARCH INSTITUTES



MEDICAL UNIVERSITY OF VIENNA



Radboudumc
university medical center

INDUSTRIAL PARTNERS



A REVOLUTION IN DIAGNOSIS
for breast cancer and muscle diseases

CONTACTS

PROJECT COORDINATOR

Dr. Françoise J. Siepel - University of Twente

Email: info@murabproject.eu

FIND US ON



www.murabproject.eu

Magnetic resonance and Ultrasound Robotic Assisted Biopsy

A NEW PARADIGM


MURAB (MRI and Ultrasound Robotic Assisted Biopsy) is a European research project, developing a new robotic assisted biopsy system.

It has the ambition to revolutionize the way diagnosis of cancer and muscle diseases are researched for patients and has the potential to save lives by early detection and treatment.



Designed for muscle and breast research, but possibly suitable for other applications.

MRI and Ultrasound combined with the precision of robotics in order to target the right place in the body.



“One in eight women will have to deal with breast cancer in their lifetime.

Early diagnosis is very important to have a better quality of life and life expectancy.

MURAB has the potential to save lives by early detection and treatment.”

Prof.dr.Ir Stefano Stramigioli
MURAB Project leader - University of Twente



EXPECTED RESULTS



**MORE
SAFETY**

REDUCTION OF PATIENT DISCOMFORT

Minimally invasive interventions, less pain and smaller wounds.



EFFICIENCY

MORE EFFICIENT BIOPSIES

Ultrasound guided biopsies are easier, faster and more accurate than before.



**TIME
SAVING**

SHORTER CLINICAL WORKFLOW

Less hospital visits, a shorter period of uncertainty.



CHEAPER

LESS HOSPITAL COSTS

Reduction in the number of over-diagnosis and subsequent overtreatment.